Results 31 to 40 of about 571,282 (185)

Research Progress of Isocitrate Dehydrogenase Gene Mutation Therapy

Xiehe Yixue Zazhi, 2023
Isocitrate dehydrogenase (IDH), a key enzyme in the tricarboxylic acid cycle, plays an important role in cellular energy metabolism. When the IDH gene is mutated, the enzyme activity is altered, resulting in an accumulation of a large amount of the tumor
LIN Meijia, ZENG Yeting, WANG Xinrui, HUANG Xiongfei   +3 more
doaj   +1 more source

Correlation of immune phenotype with IDH mutation in diffuse glioma

, 2020
BACKGROUND: Tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) are targets of immune checkpoint inhibitors. METHODS: Forty-three World Health Organization (WHO) grade II/III gliomas (39 IDH-mutant [mut], 4 IDH-wildtype [wt ...
Wilhelm, D, Kurscheid, Sebastian, Widhalm, Georg, Wohrer, A, Hegi, Monika E, Berghoff, Anna Sophie, Kiesel, Barbara, Rajky, Orsolya, Kresl, P, Marosi, Christine, Preusser, Matthias   +10 more
core   +2 more sources

IDH Mutation Analysis in Ewing Sarcoma Family Tumors [PDF]

, 2015
Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) with production of reduced nicotinamide adenine dinucleotide (NADH).
Byeong-Joo Noh, Eduardo Santini Araujo, Yong-Koo Park, Youn Wha Kim, Ji-Youn Sung, Ki Yong Na   +5 more
core   +1 more source

Prognosis in IDH-Mutant and IDH-wild type glioblastoma

, 2021
T902Glioblastoma (GBM) is the most common brain tumor in adults with a poor prognosis and predominantly astrocytic differentiation. GBM is classified according to the isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO)
Özer, Hatice, Yücel, Birsen, Yılmaz, Mukaddes, Eğilmez, Reyhan, Kılıç, Eren, Özüm, Ünal, Yeldir, Neşe   +6 more
core   +1 more source

Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.

, 2019
Background and purposeThere is increasing evidence that many IDH wildtype (IDHwt) astrocytomas have a poor prognosis and although MR features have been identified, there remains diagnostic uncertainty in the clinic.
Rees, Jeremy, Jha, Ashwani, Milic, Marina, Brandner, Sebastian, Nachev, Parashkev, Hyare, Harpreet, Thust, Stefanie, Rice, Louise   +7 more
core   +1 more source

BRAF mutation marks out specific subgroups of glioma

Glioma, 2018
Background: Molecular markers including isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion have been incorporated into the World Health Organization (WHO) 2016 classification of diffuse gliomas for integrated diagnostic reporting.
Aden Ka-Yin Chan, Riki Rui-Qi Zhang, Abudumijiti Aibaidula, Zhi Feng Shi, Hong Chen, Ying Mao, Ho Keung Ng   +6 more
doaj   +1 more source

Interlaboratory comparison of IDH mutation detection

, 2013
Isocitrate dehydrogenase (IDH) mutational testing is becoming increasingly important. For this, robust and reliable assays are needed. We tested the variation of results between six laboratories of testing for IDH mutations. Each laboratory received five
Diefes, KL, von Deimling, A, Kros, J.M., Boisselier, B, Dubbink, Erik jan; id_orcid, Strobel, T, Halling, KC, Hartmann, C, Aldape, K, van den Bent, Martin; id_orcid, Preusser, M, Sanson, M, Giannini, C   +12 more
core   +1 more source

Distributed parameter model of dynamic contrast-enhanced MRI in the identification of IDH mutation, 1p19q codeletion, and tumor cell proliferation in glioma patients. [PDF]

Front Oncol
ObjectivesTo investigate the clinical value of hemodynamic parameters derived from dynamic contrast-enhanced MRI (DCE-MRI) in predicting glioma genotypes including isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status and the tumor ...
Zhao K, Huang H, Gao E, Qi J, Chen T, Zhao G, Zhao G, Zhang Y, Wang P, Bai J, Zhang Y, Hou Z, Cheng J, Ma X.   +13 more
europepmc   +2 more sources

IDH

, 2012
Previously unpublished IDH ...
Pille Gerhold (2924181), Toomas Tammaru (826195), Javoiš, Juhan, Davis, Robert B., Õunap, Erki, Erki Õunap (3259251), Juhan Javoiš (3259248), Tammaru, Toomas, Gerhold, Pille, Robert B. Davis (3259254)   +9 more
core   +1 more source

The T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase wild-type A case report

Acta Radiologica Open, 2023
We present a case of the T2-FLAIR mismatch sign in glioblastoma, isocitrate dehydrogenase (IDH )-wild type. The T2-FLAIR mismatch sign is known as a highly specific imaging finding of astrocytoma, IDH -mutant.
Shunsuke Nishimura, Koji Yamashita, Osamu Togao, Kazufumi Kikuchi, Daisuke Kuga, Hidetaka Yamamoto, Koji Yoshimoto, Kousei Ishigami   +7 more
doaj   +1 more source